Statistics

Total Visits

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)96

Select a period of time:

Number of views in the range

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)28

Views

Views
October 20251
November 20252
December 202517
January 20262
February 20261
March 20265
April 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil10
United States3
United Kingdom2
Argentina1
Germany1
Denmark1
Algeria1
Ecuador1
Finland1
France1
 

Top cities views

Views
Algiers1
Asunción1
Brasília1
Camaçari1
Campo Grande1
Canoas1
Comodoro Rivadavia1
Cuauhtémoc1
Dakar1
Durban1